



BLISS GVS PHARMA LIMITED

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2012

SR. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2012 (UNAUDITED)	31.03.2012 (UNAUDITED)	30.06.2011 (UNAUDITED)	31.03.2012 (AUDITED)
1	Income from Operations				
	(a) Net Sales (Net of Excise Duty)				
	(b) Other Operating Income				
	Total Income from Operations (Net)	5374.16	7071.52	5208.16	26442.53
2	Expenses	59.66	67.92	16.72	224.96
	A) Consumption of Raw Materials				
	B) Purchase of Traded Goods				
	C) (Increase)/Decrease in Stock in Trade				
	D) Employee Benefit Expenses				
	E) Depreciation / Amortisation				
	F) Other Expenditure				
	Total Expenses	59.66	67.92	16.72	224.96
3	Profit from operations before other Income & Finance Cost & Exceptional items (1-2)	4354.39	5636.77	511.76	3158.95
4	Other Income	2079.43	1502.68	1703.18	19913.88
5	Profit from ordinary Activities before Finance Cost (3+4)	394.64	431.45	76.34	1620.05
6	Finance Cost	2474.67	1934.13	1778.52	8373.66
7	Profit from ordinary Activities after Finance Cost but before exceptional items (5-6)	80.57	126.34	76.08	402.41
8	Exceptional items	2393.50	1807.79	1703.46	7971.25
9	Profit from ordinary Activities before Tax (7-8)	2393.50	1807.79	1703.46	7971.25
10	Tax Expense (Including Deferred Tax)	704.01	1041.11	344.95	2688.36
11	Net Profit after Tax for the period (9-10)	1689.49	766.68	1358.51	5282.89
12	Paid - Up Equity Capital	1031.47	1031.47	1031.47	1031.47
13	Reserves Excluding Revaluation Reserve (As Per Balance Sheet)	1031.47	1031.47	1031.47	1031.47
14	Basic and Diluted EPS (Not Annualised)	1.84	0.84	1.32	5.92

SR. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2012 (UNAUDITED)	31.03.2012 (UNAUDITED)	30.06.2011 (UNAUDITED)	31.03.2012 (AUDITED)
A	PARTICULARS OF SHAREHOLDING				
1	Aggregate of Non-promoter Shareholding				
	- No. of Shares (Face Value Rs.1/- each)	36187842	36187842	37206791	36187842
	- Percentage of Shareholding (%)	35.08	35.08	36.07	35.08
2	Promoter and Promoter group Shareholding				
	A) Pledge/ Encumbered				
	- No. of Shares (Face Value Rs.1/- each)				
	- Percentage of Shares (As % of The Total Share Holding of Promoter & Promoter Group)				
	- Percentage of Shares (As % of The Total Share Capital of The Company)				
	B) Non - Encumbered				
	- No. of Shares (Face Value Rs.1/- each)	66958830	66958830	65938881	66958830
	- Percentage of Shares (As % of The Total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of The Total Share Capital of The Company)	64.92	64.92	63.93	64.92

SR. No.	PARTICULARS	QUARTER ENDED 30th June 2012
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	3
	Disposed off during the quarter	3
	REMAINING UNSOLVED AT THE END OF THE QUARTER	-

Notes:

- The company operates primarily in the pharmaceutical business and hence has only one reportable segment.
- During the current Quarter, the company has Acquired 70% Stake in Krenpoint Pharma Private Limited (KPPL) amounting to a total consideration of Rs. 18.03 Crores. Out of which consideration relating to 50% has been already paid and balance 20% is expected to be paid in near future. KPPL is engaged in Manufacturing of Pharmaceuticals and a leading company in the manufacture and export of creams, ointments and gels.
- The above results were reviewed by The Audit Committee & were there after approved By The Board at its meeting held on 10th August 2012.
- In view of the extant volatility in exchange rates and considering longer duration of exports receivables, Unrealised exchange gains aggregating to Rs. 416.95 Lakhs which would have been reported on Such exports receivables at the closing rate is not accounted for in the above interim financial statements. The same will be recognised in the books on actual settlement or at the year end which ever is earlier. The statutory auditors have brought this fact to the notice in their limited review report.

B. K. KHARE & Co.
CHARTERED ACCOUNTANTS


Emphasis of Matter

We draw attention to Note No. 4 to the Statement regarding unrealised exchange gain of Rs. 416.95 lakhs relating to exports receivables not accounted for in view of extant volatility in exchange rates and longer duration of such receivables. Our conclusion is not modified in respect of this matter.

For B. K. Khare & Co.
Chartered Accountants
Firm Registration No. 105102W

Santosh Parab
Partner
M.No.47942

Place: Mumbai
Date: 10th August 2012



Head Office : Mumbai

- Tel : (022) 2200 0607 / 7318 / 6360
(022) 6631 5835 / 36
- Fax : (022) 2200 3476
- E-mail : info@bkkhareco.com
- 706 / 708, Sharda Chambers,
New Marine Lines, Mumbai 400 020

B. K. KHARE & Co.
CHARTERED ACCOUNTANTS

The Board of Directors
Bliss GVS Pharma Limited
Mumbai.

Dear Sirs,

Limited Review Report

We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Bliss GVS Pharma Limited for the period ended 30th June, 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by